To investigate the clinical effects of atorvastatin in the treatment of postoperative recurrent chronic subdural hematoma.

From January 2014 to September 2015, 17 patients in the first people’s hospital of xiangyang were selected as research objects. These patients received oral atorvastatin and the patient’s symptoms, daily life ability ADL score, the degree of absorption of the hematoma were observed to determine the efficacy on admission and 1th, 2th week, 1th, 3th month after the therapy.

On 1th week the symptoms improved in 13 (13/16, 81.25%) cases, ADL score increased in (15/16, 93.75%) cases (P<0.05). On 2th week the hematoma were began to reduce (P<0.05). On 3th month, ADL score returned to normal, the symptoms improved completely, and the intracranial hematoma was completely absorbed in 15 cases. ADL score returned to normal, the symptoms improved significantly, most of the intracranial hematoma was absorbed in one case. One patient complicated with acute cholecystitis and abnormal liver function, his condition deteriorated with an enlarged hematoma during the 2th week of treatment and was cured by skull drilling drainage and postoperative oral atorvastatin again.

Atorvastatin in the treatment of postoperative recurrent chronic subdural hematoma has a significant effect, but caution is needed for patients with abnormal liver function.